Advertisement
DXR vs SHC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXR is a StrongBuy and SHC is a Hold.
DXR's RSI Indicator dives oversold zone
The RSI Indicator for DXR moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXR as a result. In 97 of 127 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for DXR turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 50 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.061) is normal, around the industry mean (4.961). P/E Ratio (5.574) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.013) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SHC's Indicator enters downward trend
The Aroon Indicator for SHC entered a downward trend on October 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator formed such a pattern. In 168 of the 210 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
SHC moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SHC crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 62 cases where SHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on SHC as a result. In 57 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for SHC just turned positive on October 22, 2026. Looking at past instances where SHC's MACD turned positive, the stock continued to rise in 26 of 38 cases over the following month. The odds of a continued upward trend are 68%.
Following a +0.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHC advanced for three days, in 187 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
SHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. SHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.773) is normal, around the industry mean (66.046). P/E Ratio (31.807) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.313) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
DXR | SHC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 59 | 35 | |
PRICE GROWTH RATING 1..100 | 73 | 50 | |
P/E GROWTH RATING 1..100 | 96 | 96 | |
SEASONALITY SCORE 1..100 | 42 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DXR's Valuation (73) in the Medical Specialties industry is in the same range as SHC (77) in the null industry. This means that DXR’s stock grew similarly to SHC’s over the last 12 months.
DXR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as SHC (100) in the null industry. This means that DXR’s stock grew similarly to SHC’s over the last 12 months.
SHC's SMR Rating (35) in the null industry is in the same range as DXR (59) in the Medical Specialties industry. This means that SHC’s stock grew similarly to DXR’s over the last 12 months.
SHC's Price Growth Rating (50) in the null industry is in the same range as DXR (73) in the Medical Specialties industry. This means that SHC’s stock grew similarly to DXR’s over the last 12 months.
SHC's P/E Growth Rating (96) in the null industry is in the same range as DXR (96) in the Medical Specialties industry. This means that SHC’s stock grew similarly to DXR’s over the last 12 months.
| DXR | SHC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | N/A |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 72% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 73% |
| Advances ODDS (%) | N/A | 10 days ago 68% |
| Declines ODDS (%) | 1 day ago 73% | 4 days ago 70% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXR’s FA Score shows that 0 FA rating(s) are green while SHC’s FA Score has 0 green FA rating(s).
- DXR’s FA Score: 0 green, 5 red.
- SHC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXR’s TA Score shows that 2 TA indicator(s) are bullish while SHC’s TA Score has 3 bullish TA indicator(s).
- DXR’s TA Score: 2 bullish, 7 bearish.
- SHC’s TA Score: 3 bullish, 5 bearish.
Price Growth
DXR (@Pharmaceuticals: Other) experienced а -4.33% price change this week, while SHC (@Medical Specialties) price change was +0.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
DXR is expected to report earnings on Nov 12, 2026.
SHC is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
DXR and
Correlation & Price change
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -3.09% | ||
| IART - DXR | 33% Poorly correlated | +4.10% | ||
| BWAY - DXR | 27% Poorly correlated | -4.51% | ||
| AVTR - DXR | 23% Poorly correlated | -0.64% | ||
| COO - DXR | 20% Poorly correlated | +4.54% | ||
| SHC - DXR | 20% Poorly correlated | +2.03% | ||
More | ||||
SHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, SHC has been loosely correlated with RVTY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SHC jumps, then RVTY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FAB | 105.81 | 2.12 | +2.04% |
| First Trust Multi Cap Value AlphaDEX Fund (FAB) | |||
| SPCK | 21.60 | 0.15 | +0.70% |
| SPAC and New Issue ETF (SPCK) | |||
| VTES | 100.14 | 0.50 | +0.50% |
| Vanguard Short-Term Tax Exempt Bond ETF (VTES) | |||
| CPSD | 27.26 | N/A | N/A |
| Calamos S&P 500 Structured Alt Protection ETF - December (CPSD) | |||
| EPU | 84.80 | -3.91 | -4.41% |
| iShares MSCI Peru and Global Exposure ETF (EPU) | |||